Loss in life expectancy in Patients with Stage II-III cutaneous melanoma in Sweden: a population-based cohort study

BACKGROUND:Survival in cutaneous melanoma (CM) is heterogeneous. Loss in life expectancy (LLE) measures impact of CM on remaining lifespan compared to general population. OBJECTIVES:Investigating LLE in operated stage II-III CM patients. METHODS:Data from 8,061 patients (aged 40-80 years) with stage II-III CM in Sweden, diagnosed between 2005-2018 were analyzed (Swedish Melanoma Registry). A flexible parametric survival model estimated life expectancy and LLE. RESULTS:Based on 2018 diagnoses, stage II and III CM patients lost 2209 and 1902 life years, respectively. LLE was higher in stage III: 5.2 vs 10.9 years (stage II vs III 60-year-old females). Younger patients had higher LLE: 10.7 vs 3.9 years (stage II CM in 40 vs 70-year-old males). In stage II, females had lower LLE than males; 50-year-old females and males stage II CM had LLE equal to 7.3 and 8.3 years, respectively. LLE increased with higher substages, stage IIB resembling IIIB and IIC resembling IIIC-D. LIMITATIONS:Extrapolation was used to estimate LLE. Varying stage group sizes require caution. CONCLUSIONS:Our results are both clinically relevant and easy-to-interpret measures of the impact of CM on survival, but the results also summarize the prognosis over the lifetime of a CM patient.